

# Initial Prior Authorization

## Viberzi

### Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Viberzi	eluxadoline

### Indications

#### FDA-approved Indications

Viberzi is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

### Coverage Criteria

#### Irritable Bowel Syndrome with Diarrhea (IBS-D)

Authorization may be granted when the requested drug is being prescribed for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in an adult patient when the following criteria is met:

- The patient does NOT have ANY of the following:
  - A history of cholecystectomy
  - A history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction
  - Known or suspected biliary duct obstruction or sphincter of Oddi disease or dysfunction

Reference number(s)
1287-A, 1271-A

- A history of pancreatitis or structural diseases of the pancreas, including known or suspected pancreatic duct obstruction
- Severe hepatic impairment (Child-Pugh Class C)
- Alcoholism, alcohol abuse or alcohol addiction, or a patient who drinks more than 3 alcoholic beverages per day

## Duration of Approval (DOA)

- 1287-A: DOA: 36 months
- 1271-A: DOA: 12 months

## References

1. Viberzi [package insert]. Madison, NJ: Allergan USA, Inc; July 2024.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed August 26, 2024.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 08/26/2024).